Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

The Optimal Treatment for Stage IIIA-N2 Non-small-cell Lung Cancer: A Network Meta-analysis

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Postmarket Experience With HeartMate 3 Left Ventricular Assist Device: 30-Day Outcomes From the ELEVATE Registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Exploring Shared Mental Models of surgical teams in Video-Assisted Thoracoscopic Surgery lobectomy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The Use of Topical Hemostatic Agents in Cardiothoracic Surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Important Non-Technical Skills in Video-Assisted Thoracoscopic Surgery Lobectomy: Team Perspectives

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Endocarditis in a Quadricuspid Aortic Valve

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Exploring Shared Mental Models of surgical teams in Video-Assisted Thoracoscopic Surgery lobectomy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Oxidized resorbable cellulose (Gelita-cel) causing foreign body reaction in the mediastinum

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Society for Translational Medicine expert consensus on the use of antibacterial drugs in thoracic surgery

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. A novel assessment tool for evaluating competence in video-assisted thoracoscopic surgery lobectomy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • AME Thoracic Surgery Collaborative Group
Vis graf over relationer

BACKGROUND: The optimal treatment for stage IIIA-N2 non-small-cell lung cancer (NSCLC) is controversial. We aimed to address this important issue through a Bayesian network meta-analysis.

METHODS: We performed a search of electronic databases for randomized controlled trials comparing the following treatments: surgery, radiotherapy, chemotherapy and their multiple combinations before March 25, 2018. Pooled data on overall survival and treatment-related deaths were analyzed within the Bayesian framework.

RESULTS: Eighteen eligible trials reporting 13 treatments were included. In terms of overall survival, neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy or radiotherapy, which tended to be consistent (hazard ratio 1.14, 95% credible interval 0.21-5.93), ranked superior to other treatments. Notably, neoadjuvant chemotherapy followed by surgery and adjuvant radiotherapy was significantly more effective in prolonging survival than surgery alone (0.38, 0.18-0.81), surgery plus adjuvant radiotherapy (0.51, 0.29-0.92) and potentially surgery plus adjuvant chemotherapy (0.49, 0.23-1.05). Overall, with 29% as the highest possibility of causing the fewest treatment-related deaths, neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy or radiotherapy was the safest treatment option.

CONCLUSIONS: Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy or radiotherapy has the greatest possibility to be the optimal treatment with the best overall survival and fewest treatment-related deaths for stage IIIA-N2 NSCLC.

OriginalsprogEngelsk
TidsskriftThe Annals of thoracic surgery
ISSN0003-4975
DOI
StatusE-pub ahead of print - 2019

ID: 56588318